ERBB2 and neoplasm: Other population characteristics included invasive cancers (82.3%), a larger tumour size > 20 mm (44.4%), stage I (68.4%), lower grade 1–2 (62.2%), HER2 negative (82.8%) for those with invasive disease, and hormone receptor positive (84%) for those with invasive disease.